Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06294600 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

Study acronym: REACT
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 16, 2025 (before its estimated April 5, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 22 to 24
    • Primary completion date: Nov 5, 2025 to Apr 5, 2026
    • Study completion date: Jan 30, 2026 to Jul 30, 2026
    v12
  2. Site details revised at 2 of 22 sitesv11
  3. Site details revised at 3 of 22 sitesv10
  4. Site details revised at 1 of 22 sitesv9
  5. Site details revised at 4 of 22 sitesv8
Show 6 earlier versionsHide 6 earlier versions
  1. Site details revised at 2 of 22 sitesv7
  2. Site details revised at 4 of 22 sitesv6
  3. Site details revised at 1 of 22 sitesv5
  4. Site details revised at 2 of 22 sitesv4
  5. Site details revised at 2 of 22 sitesv3
  6. Lead sponsor: Evangelos Giamarellos-Bourboulis to Hellenic Institute for the Study of Sepsisv2 Show 4 more changesShow less
    • Primary endpoints revised (3)
    • Interventions: Clarithromycin (Drug), Tablets (Drug) to Clarithromycin 500mg (Drug), Tablets (Drug)
    • Secondary endpoints revised (9)
    • Study description expanded, about 2 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early start of adjunctive oral clarithromycin guided by suPAR to prevent the progression into sepsis in patients with community-acquired pneumonia (CAP) at risk. This can be achieved by endpoints incorporating clinical benefit with the effect of treatment on the improvement of the immune dysregulation of CAP. The secondary objectives of REACT are to investigate the impact of early adjunctive treatment with clarithromycin on the resolution of CAP at the test-of-cure (TOC) visit.
Trial Details
NCT Number NCT06294600
Lead Sponsor Hellenic Institute for the Study of Sepsis
Conditions
(from sponsor)		 Community-acquired Pneumonia
Related terms Community-Acquired Pneumonia, Sepsis
Enrollment 330 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov